Advertisement
Screener

IBIO, INC. (IBIO) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

1.8 / 5 stars · 30/82 Roast Me

IBIO, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

IBIO, INC. (IBIO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.59 million for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-15.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-09-15

  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$525.00K.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$303.00K.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$163.00K, a 1353.85% decline year-over-year.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$602.00K.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$1.59M.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$68.00K.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$215.00K.
  • IBIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$259.00K.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filedNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2017-06-30-$525.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-15
-$828.00K
derived: sum of 2 quarters · filed 2017-09-15
-$991.00K
derived: sum of 3 quarters · filed 2017-09-15
-$1.59M
10-K · filed 2017-09-15
2017-03-31-$303.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15
-$466.00K
derived: sum of 2 quarters · filed 2017-05-15
-$1.07M
10-Q · filed 2017-05-15
-$1.13M
derived: sum of 4 quarters · filed 2017-09-15
2016-12-31-$163.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-21
-$765.00K
10-Q · filed 2017-02-21
-$825.00K
derived: sum of 3 quarters · filed 2017-09-15
-$828.00K
derived: sum of 4 quarters · filed 2017-09-15
2016-09-30-$602.00K
10-Q · filed 2016-11-18
-$662.00K
derived: sum of 2 quarters · filed 2017-09-15
-$665.00K
derived: sum of 3 quarters · filed 2017-09-15
-$652.00K
derived: sum of 4 quarters · filed 2017-09-15
2016-06-30-$60.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-15
-$63.00K
derived: sum of 2 quarters · filed 2017-09-15
-$50.00K
derived: sum of 3 quarters · filed 2017-09-15
-$68.00K
10-K · filed 2017-09-15
2016-03-31-$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15
$10.00K
derived: sum of 2 quarters · filed 2017-05-15
-$8.00K
10-Q · filed 2017-05-15
-$71.00K
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31$13.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-21
-$5.00K
10-Q · filed 2017-02-21
-$68.00K
derived: sum of 3 quarters · filed 2017-02-21
-$120.00K
derived: sum of 4 quarters · filed 2017-02-21
2015-09-30-$18.00K
10-Q · filed 2016-11-18
-$81.00K
derived: sum of 2 quarters · filed 2016-11-18
-$133.00K
derived: sum of 3 quarters · filed 2016-11-18
-$202.00K
derived: sum of 4 quarters · filed 2016-11-18
2015-06-30-$63.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13
-$115.00K
derived: sum of 2 quarters · filed 2016-10-13
-$184.00K
derived: sum of 3 quarters · filed 2016-10-13
-$215.00K
10-K · filed 2016-10-13
2015-03-31-$52.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-23
-$121.00K
derived: sum of 2 quarters · filed 2016-05-23
-$152.00K
10-Q · filed 2016-05-23
-$211.00K
derived: sum of 4 quarters · filed 2016-05-23
2014-12-31-$69.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-22
-$100.00K
10-Q · filed 2016-02-22
-$159.00K
derived: sum of 3 quarters · filed 2016-02-22
-$277.00K
derived: sum of 4 quarters · filed 2016-02-22
2014-09-30-$31.00K
10-Q · filed 2015-11-13
-$90.00K
derived: sum of 2 quarters · filed 2015-11-13
-$208.00K
derived: sum of 3 quarters · filed 2015-11-13
-$231.00K
derived: sum of 4 quarters · filed 2015-11-13
2014-06-30-$59.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-10-13
-$177.00K
derived: sum of 2 quarters · filed 2015-10-13
-$200.00K
derived: sum of 3 quarters · filed 2015-10-13
-$259.00K
10-K · filed 2015-10-13
2014-03-31-$118.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-15
-$141.00K
derived: sum of 2 quarters · filed 2015-05-15
-$200.00K
10-Q · filed 2015-05-15
-$237.00K
derived: sum of 4 quarters · filed 2015-05-15
2013-12-31-$23.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-24
-$82.00K
10-Q · filed 2015-02-24
-$119.00K
derived: sum of 3 quarters · filed 2015-02-24
-$166.00K
derived: sum of 4 quarters · filed 2015-02-24
2013-09-30-$59.00K
10-Q · filed 2014-11-14
-$96.00K
derived: sum of 2 quarters · filed 2014-11-14
-$143.00K
derived: sum of 3 quarters · filed 2014-11-14
2013-06-30-$37.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29
-$84.00K
derived: sum of 2 quarters · filed 2014-09-29
-$195.00K
10-K · filed 2014-09-29
2013-03-31-$47.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-15
-$158.00K
10-Q · filed 2014-05-15
2012-12-31-$111.00K
10-Q · filed 2014-02-14
-$2.69M
10-Q · filed 2013-02-19
2011-12-31-$2.01M
10-Q · filed 2013-02-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
MAIA Biotechnology, Inc. (MAIA)United States$0.077B-2.30
Valion Bio, Inc. (VBIO)United States$0.077B
Adicet Bio, Inc. (ACET)United States$0.078B-0.81
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
Lifevantage Corp (LFVN)United States$0.078B15.40
OS Therapies Inc (OSTX)United States$0.076B-2.17
Gain Therapeutics, Inc. (GANX)United States$0.080B-4.40
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
Cingulate Inc. (CING)United States$0.073B-2.64
Spero Therapeutics, Inc. (SPRO)United States$0.073B17.41